Alcon Enters Nasal Market With Approval Of Seasonal Allergic Rhinitis Spray
This article was originally published in The Pink Sheet Daily
Executive Summary
Swiss eye care company wins FDA approval of Patanase after withdrawal and resubmission of NDA.
You may also be interested in...
Novartis To Acquire Majority Stake In Alcon
Deal offers synergies with firm’s Ciba Vision affiliate and ex-U.S. marketing rights to Lucentis.
Alcon Could Re-File Patanase Nasal Spray NDA By End Of 2007
Olopatadine reformulation will require additional preclinical testing, firm says.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.